Go To Global Site
Willkommen bei UCB in Deutschland

UCB CEO, Roch Doliveux, to chair Innovative Medicines Initiative board for a second term

Roch Doliveux to spearhead industry’s commitment to world’s biggest public-private partnership in biopharmaceutical research and innovation

Brussels (Belgium), April 1, 2014 – 9:00 AM (CET) – UCB and IMI announced today that CEO Roch Doliveux has again been appointed Chair of the Governing Board of the Innovative Medicines Initiative (IMI), a public-private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA). UCB has been a member of IMI since its initiation in 2006 with Roch Doliveux joining the IMI Governing Board in May 2010, and Chairing the IMI Governing Board from 2012 to 2013.